Improved Tumor Targeting of Salmonella VNP20009 via Ice-llama Antibody Guidance
通过 Ice-llama 抗体指导改进沙门氏菌 VNP20009 的肿瘤靶向
基本信息
- 批准号:8492399
- 负责人:
- 金额:$ 19.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-04-01 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAdverse effectsAnimal ModelAntibioticsAntibodiesAttenuatedBacteriaBenchmarkingBindingBioluminescenceBreast Cancer CellCancer PatientCancer cell lineCarcinoembryonic AntigenCause of DeathCell Culture TechniquesCell surfaceCellsCessation of lifeColony-forming unitsDiagnosisDrug Delivery SystemsEngineeringEnzyme-Linked Immunosorbent AssayEquilibriumFluorescence MicroscopyGastrointestinal NeoplasmsGene FusionGeneticGoalsGrowthHeart DiseasesHumanIceImmunohistochemistryIn SituIn VitroLinkLlamaLongitudinal StudiesMCF7 cellMalignant NeoplasmsMeasurementMediatingMembrane ProteinsMetastatic MelanomaModelingMolecularMonitorNanostructuresNecrosisOrganOutcomePatientsPlasmidsProteinsRadioResistanceSalmonellaSalmonella entericaSolutionsStagingSurfaceSystemTherapeuticTimeTissue HarvestingTitrationsToxic effectTumor Cell InvasionTumor MarkersVirusWomanXenograft Modelantigen bindingbasedesignimprovedin vivoluminescencemalignant breast neoplasmmouse modelneoplastic cellpublic health relevanceresearch studytumor
项目摘要
DESCRIPTION (provided by applicant): ABSTRACT While Salmonella VNP 20009 (VNP) has shown promise in tumor targeting in animal models it is becoming apparent that regrowth of tumors is the outcome since the bacteria preferentially grow in the necrotic core and fail to reach
the vital periphery. In human trials of metastatic melanoma patients, even targeting itself was very poor and no tumor regression was observed. We aim to improve the tumor targeting and tumor regressive ability of VNP by conferring upon it the successful recognition potential of antibody mediated tumor targeting. We had previously attempted to do this using the lpp-OmpA surface display platform and poorly soluble scFv antibodies but have since found out that the combination caused bacterial growth arrest and restricted the therapeutic potential of engineered VNP. We hypothesize that VNP displaying small and highly soluble anti- CEA single domain antibodies via the ice nucleation protein (INP) will show enhanced targeting of CEA positive tumors without inhibiting bacterial invasion or replication and will therefore be able to regress tumors more effectively than parental VNP. Our specific aims are to; 1, Engineer VNP to display anti-CEA sdAb without impeding replication, yet capable of binding immobilized CEA in vitro; 2, Demonstrate engineered VNP is capable of being internalized in MCF-7 cells and is also capable of homogenous targeting in three- dimensional spheroidal cell culture models; 3, Demonstrate improved in vivo tumor targeting of engineered VNP in a mouse model of breast cancer, elucidating intra-tumoral distribution and potential for complete tumor regression. The multifunctional capabilities of VNP including mobility and ability to carry large payloads are well
balanced by the ability to visualize single bioluminescent cells and facile elimination of the bacteria by antibiotics. As such, the potential for VNP as a highly controllable yet versatile cancer therapeutic is enormous so long as we can improve targeting and regressive capacity.
描述(申请人提供)摘要虽然沙门氏菌vnp 20009(Vnp)已在动物模型中显示出在肿瘤靶向方面的前景,但很明显,肿瘤的再生长是结果,因为细菌优先生长在坏死的核心,无法到达
重要的外围设备。在转移性黑色素瘤患者的人体试验中,即使靶向本身也很差,没有观察到肿瘤消退。我们的目的是通过赋予VNP抗体介导的肿瘤靶向的成功识别潜力来提高VNP的肿瘤靶向性和肿瘤消退能力。我们之前曾试图使用LPP-OmpA表面展示平台和难溶的单链抗体来做到这一点,但后来发现,这两种抗体的结合导致细菌生长停滞,并限制了工程VNP的治疗潜力。我们推测,通过冰核蛋白(INP)展示小而高度可溶性的抗CEA单域抗体的VNP将在不抑制细菌侵袭或复制的情况下增强对CEA阳性肿瘤的靶向性,因此将能够比亲本VNP更有效地逆转肿瘤。我们的具体目标是:1、在不妨碍复制的情况下展示抗CEA sdAb的基因工程VNP,在体外能够结合固定化CEA的CEA;2、证明基因工程VNP能够内化到MCF-7细胞中,并且在三维球状细胞培养模型中具有同质靶向性;3、在小鼠乳腺癌模型中证明基因工程VNP具有更好的体内肿瘤靶向性,阐明肿瘤内的分布和肿瘤完全消退的可能性。VNP的多功能功能很好,包括移动性和携带大型有效载荷的能力
通过显示单个生物发光细胞的能力和通过抗生素轻松消除细菌的能力来平衡。因此,VNP作为一种高度可控且通用的癌症治疗方法的潜力是巨大的,只要我们能够提高靶向和后退能力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW HAYHURST其他文献
ANDREW HAYHURST的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW HAYHURST', 18)}}的其他基金
Novel antiviral strategy offering forward capability and reduced risk of escape
新颖的抗病毒策略提供前进能力并降低逃逸风险
- 批准号:
10593778 - 财政年份:2023
- 资助金额:
$ 19.9万 - 项目类别:
Nanobody toolkit for human coronavirus classification
用于人类冠状病毒分类的纳米抗体工具包
- 批准号:
10218812 - 财政年份:2021
- 资助金额:
$ 19.9万 - 项目类别:
Nanobody toolkit for human coronavirus classification
用于人类冠状病毒分类的纳米抗体工具包
- 批准号:
10375561 - 财政年份:2021
- 资助金额:
$ 19.9万 - 项目类别:
Mechanism and Evolution of Filoviral Monoclonal Affinity Reagent Sandwich Assays
丝状病毒单克隆亲和试剂三明治检测的机制和演变
- 批准号:
9204379 - 财政年份:2015
- 资助金额:
$ 19.9万 - 项目类别:
Rapid Ligand Pairing Strategy to Simplify Diagnostic Immunoassay Assembly
简化诊断免疫测定组装的快速配体配对策略
- 批准号:
8492614 - 财政年份:2013
- 资助金额:
$ 19.9万 - 项目类别:
Improved Tumor Targeting of Salmonella VNP20009 via Ice-llama Antibody Guidance
通过 Ice-llama 抗体指导改进沙门氏菌 VNP20009 的肿瘤靶向
- 批准号:
8637021 - 财政年份:2013
- 资助金额:
$ 19.9万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 19.9万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 19.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 19.9万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 19.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 19.9万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 19.9万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 19.9万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 19.9万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 19.9万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 19.9万 - 项目类别:
Studentship














{{item.name}}会员




